Baseline characteristics
| . | Haplo-PTCy . | MSD-PTCy . | P . | Younger haplo-PTCy . | Older MSD-PTCy . | P . |
|---|---|---|---|---|---|---|
| n = 1052 . | n = 400 . | n = 347 . | n = 143 . | |||
| Patient age, y | .12 | - | ||||
| <50 | 539 (51.2) | 223 (55.8) | 347 (100) | 143 (100) | ||
| ≥50 | 513 (48.8) | 177 (44.2) | ||||
| Median (IQR) | 49.1 (31.7-63.3) | 46.2 (31.2-59.5) | .03 | 59.4 (55.1-64) | 61.2 (56.6-66) | .02 |
| Donor age | .11 | |||||
| Median (IQR) | 39.1 (29.7-47.6) | 44.7 (30-56.3) | <.0001 | 28.1 (24.1-31.5) | 58.9 (54.9-63.5) | <.0001 |
| Sex | .66 | .71 | ||||
| Male | 623 (59.2) | 242 (60.5) | 217 (62.5) | 92 (64.3) | ||
| Female | 429 (40.8) | 158 (39.5) | 130 (37.5) | 51 (35.7) | ||
| Disease | .47 | .06 | ||||
| AML/ALL | 877 (83.4) | 327 (81.8) | 260 (74.9) | 95 (66.4) | ||
| MDS | 175 (16.6) | 73 (18.2) | 87 (25.1) | 48 (33.6) | ||
| Disease stage | .79 | .35 | ||||
| Early-intermediate | 749 (71.2) | 288 (72) | 240 (69.2) | 92 (64.3) | ||
| Advanced | 296 (28.1) | 110 (27.5) | 107 (30.8) | 50 (35) | ||
| Missing | 7 (0.7) | 2 (0.5) | - | 1 (0.7) | ||
| Conditioning | .48 | .19 | ||||
| MAC | 557 (53) | 220 (55) | 110 (31.7) | 54 (37.8) | ||
| RIC/NMA | 495 (47) | 180 (45) | 237 (68.3) | 89 (62.2) | ||
| Graft type | .17 | .28 | ||||
| PB | 672 (63.9) | 271 (67.8) | 235 (67.7) | 104 (72.7) | ||
| BM | 380 (36.1) | 129 (32.2) | 112 (32.3) | 39 (27.3) | ||
| KPS | .94 | .51 | ||||
| <90 | 431 (41) | 166 (41.5) | 168 (48.4) | 75 (52.4) | ||
| ≥90 | 594 (56.5) | 231 (57.8) | 171 (49.3) | 67 (46.8) | ||
| Missing | 27 (2.6) | 3 (0.8) | 8 (2.3) | 1 (0.7) | ||
| HCT-CI | .24 | .32 | ||||
| 0-2 | 558 (53) | 226 (56.5) | 170 (49) | 63 (44.1) | ||
| ≥3 | 494 (47) | 174 (43.5) | 177 (51) | 80 (55.9) | ||
| D/R CMV | .89 | .16 | ||||
| Pos/Pos | 475 (45.2) | 171 (42.8) | 138 (39.8) | 59 (41.3) | ||
| Pos/Neg | 92 (8.8) | 36 (9) | 22 (6.3) | 15 (10.5) | ||
| Neg/Pos | 280 (26.6) | 99 (24.8) | 111 (32) | 33 (23.1) | ||
| Neg/Neg | 198 (18.8) | 79 (19.8) | 75 (21.6) | 32 (22.4) | ||
| Missing | 7 (0.7) | 15 (3.8) | 1 (0.3) | 4 (2.8) | ||
| D/R sex | .75 | .24 | ||||
| Others | 815 (77.5) | 313 (78.2) | 274 (79) | 106 (74.1) | ||
| Fem-to-Male | 237 (22.5) | 87 (21.8) | 73 (21) | 37 (25.9) | ||
| Race | .79 | .94 | ||||
| White | 743 (70.6) | 279 (69.8) | 260 (74.9) | 109 (76.2) | ||
| Others | 244 (23.2) | 95 (23.8) | 75 (21.6) | 32 (22.4) | ||
| Missing | 65 (6.2) | 26 (6.4) | 12 (3.5) | 2 (1.4) | ||
| Time to HCT, median months (IQR) | 7 (4.5-14.5) | 6.7 (4.3-12.5) | .15 | 6.1 (4.2-10.9) | 6.7 (4.4-10.4) | .42 |
| Year of HCT, median (IQR) | 2016 (2015-2017) | 2016 (2015-2016) | <.0001 | 2016 (2015-2017) | 2015 (2015-2016) | <.0001 |
| Follow-up among survivors, median months (IQR) | 32.3 (24-43) | 24.4 (12.5-36.7) | <.0001 | 35.1 (24.1-39.7) | 24.1 (12.4-37) | .0019 |
| . | Haplo-PTCy . | MSD-PTCy . | P . | Younger haplo-PTCy . | Older MSD-PTCy . | P . |
|---|---|---|---|---|---|---|
| n = 1052 . | n = 400 . | n = 347 . | n = 143 . | |||
| Patient age, y | .12 | - | ||||
| <50 | 539 (51.2) | 223 (55.8) | 347 (100) | 143 (100) | ||
| ≥50 | 513 (48.8) | 177 (44.2) | ||||
| Median (IQR) | 49.1 (31.7-63.3) | 46.2 (31.2-59.5) | .03 | 59.4 (55.1-64) | 61.2 (56.6-66) | .02 |
| Donor age | .11 | |||||
| Median (IQR) | 39.1 (29.7-47.6) | 44.7 (30-56.3) | <.0001 | 28.1 (24.1-31.5) | 58.9 (54.9-63.5) | <.0001 |
| Sex | .66 | .71 | ||||
| Male | 623 (59.2) | 242 (60.5) | 217 (62.5) | 92 (64.3) | ||
| Female | 429 (40.8) | 158 (39.5) | 130 (37.5) | 51 (35.7) | ||
| Disease | .47 | .06 | ||||
| AML/ALL | 877 (83.4) | 327 (81.8) | 260 (74.9) | 95 (66.4) | ||
| MDS | 175 (16.6) | 73 (18.2) | 87 (25.1) | 48 (33.6) | ||
| Disease stage | .79 | .35 | ||||
| Early-intermediate | 749 (71.2) | 288 (72) | 240 (69.2) | 92 (64.3) | ||
| Advanced | 296 (28.1) | 110 (27.5) | 107 (30.8) | 50 (35) | ||
| Missing | 7 (0.7) | 2 (0.5) | - | 1 (0.7) | ||
| Conditioning | .48 | .19 | ||||
| MAC | 557 (53) | 220 (55) | 110 (31.7) | 54 (37.8) | ||
| RIC/NMA | 495 (47) | 180 (45) | 237 (68.3) | 89 (62.2) | ||
| Graft type | .17 | .28 | ||||
| PB | 672 (63.9) | 271 (67.8) | 235 (67.7) | 104 (72.7) | ||
| BM | 380 (36.1) | 129 (32.2) | 112 (32.3) | 39 (27.3) | ||
| KPS | .94 | .51 | ||||
| <90 | 431 (41) | 166 (41.5) | 168 (48.4) | 75 (52.4) | ||
| ≥90 | 594 (56.5) | 231 (57.8) | 171 (49.3) | 67 (46.8) | ||
| Missing | 27 (2.6) | 3 (0.8) | 8 (2.3) | 1 (0.7) | ||
| HCT-CI | .24 | .32 | ||||
| 0-2 | 558 (53) | 226 (56.5) | 170 (49) | 63 (44.1) | ||
| ≥3 | 494 (47) | 174 (43.5) | 177 (51) | 80 (55.9) | ||
| D/R CMV | .89 | .16 | ||||
| Pos/Pos | 475 (45.2) | 171 (42.8) | 138 (39.8) | 59 (41.3) | ||
| Pos/Neg | 92 (8.8) | 36 (9) | 22 (6.3) | 15 (10.5) | ||
| Neg/Pos | 280 (26.6) | 99 (24.8) | 111 (32) | 33 (23.1) | ||
| Neg/Neg | 198 (18.8) | 79 (19.8) | 75 (21.6) | 32 (22.4) | ||
| Missing | 7 (0.7) | 15 (3.8) | 1 (0.3) | 4 (2.8) | ||
| D/R sex | .75 | .24 | ||||
| Others | 815 (77.5) | 313 (78.2) | 274 (79) | 106 (74.1) | ||
| Fem-to-Male | 237 (22.5) | 87 (21.8) | 73 (21) | 37 (25.9) | ||
| Race | .79 | .94 | ||||
| White | 743 (70.6) | 279 (69.8) | 260 (74.9) | 109 (76.2) | ||
| Others | 244 (23.2) | 95 (23.8) | 75 (21.6) | 32 (22.4) | ||
| Missing | 65 (6.2) | 26 (6.4) | 12 (3.5) | 2 (1.4) | ||
| Time to HCT, median months (IQR) | 7 (4.5-14.5) | 6.7 (4.3-12.5) | .15 | 6.1 (4.2-10.9) | 6.7 (4.4-10.4) | .42 |
| Year of HCT, median (IQR) | 2016 (2015-2017) | 2016 (2015-2016) | <.0001 | 2016 (2015-2017) | 2015 (2015-2016) | <.0001 |
| Follow-up among survivors, median months (IQR) | 32.3 (24-43) | 24.4 (12.5-36.7) | <.0001 | 35.1 (24.1-39.7) | 24.1 (12.4-37) | .0019 |
ALL, acute lymphoblastic leukemia; BM, bone marrow; CMV, cytomegalovirus; D/R, donor/recipient; HCT-CI, HCT comorbidity index; Fem-to-Male, female donor to male recipient; Haplo, haploidentical; IQR, interquartile range; KPS, Karnofsky performance status score; MAC, myeloablative conditioning; Neg, negative; NMA; nonmyeloablative conditioning; PB, peripheral blood; Pos, positive; RIC, reduced-intensity conditioning.